Sign In to Request a Protocol
Sign In to Request a Protocol

Tesamorelin (20 mg Vial)

  • Table of Contents

Tesamorelin Research Information Guide

This Tesamorelin information is provided for general educational and research reference only. This page covers background information, scientific context, and product-related details for educational purposes.
  • Product Information: General information about Tesamorelin and its research background.
  • Research Context: Tesamorelin is a synthetic peptide studied for its relationship with growth hormone pathways and metabolic research.
  • Scientific Background: Research has explored Tesamorelin’s mechanisms, biological activity, and potential applications in scientific studies.
  • Storage: Refer to the product-specific information and manufacturer guidelines for handling and storage details.
Tesamorelin is a synthetic peptide analog related to growth hormone-releasing hormone (GHRH). It has been studied in scientific research involving growth hormone pathways, metabolism, and related biological processes.
Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety considerations, read Tesamorelin Peptide: Product Information Guide.
  • Dosing & Reconstitution Guide

Educational guide covering research background, product information, and scientific context.

Standard FDA-Approved Protocol (3.0 mL = ~6.67 mg/mL)

Route: Subcutaneous injection | Frequency: Once daily

WeekDaily Dose (mg / mcg)Units (per injection) (mL)
Week 11 mg / 1000 mcg15 units (0.15 mL)
Weeks 2–12+2 mg / 2000 mcg30 units (0.30 mL)
Frequency: Inject once daily subcutaneously, preferably in the evening to coincide with nocturnal GH release. The 2 mg daily dose is the standard FDA-approved regimen for HIV lipodystrophy. A one-week titration at 1 mg may improve tolerability before advancing to the full 2 mg dose.

Reconstitution Steps

  • 1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  • 2. Inject slowly down the vial wall; avoid foaming.
  • 3. Gently swirl until dissolved (do not shake).
  • 4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  • 5. Use within 7 days when reconstituted with bacteriostatic water[1].

Important: This guide is for educational purposes only and is not medical advice.

  • Product Details​
  • Peptide Vials (Tesamorelin, 20 mg each):
  • 8 weeks ≈ 6 vials (105 mg total)
  • 12 weeks ≈ 9 vials (161 mg total)
  • 16 weeks ≈ 11 vials (217 mg total)
  • Insulin Syringes (U-100, 1 mL capacity):
  • Per week: 7 syringes
  • 8 weeks: 56 syringes
  • 12 weeks: 84 syringes
  • 16 weeks: 112 syringes
  • Bacteriostatic Water (10 mL bottles):
  • 8 weeks: 18 mL → 2 × 10 mL bottles
  • 12 weeks: 27 mL → 3 × 10 mL bottles
  • 16 weeks: 33 mL → 4 × 10 mL bottles
  • One for the vial stopper + one for the research process.
  • Per week: 14 swabs
  • 8 weeks: 112 swabs → recommend 2 × 100-count boxes
  • 12 weeks: 168 swabs → recommend 2 × 100-count boxes
  • 16 weeks: 224 swabs → recommend 3 × 100-count boxes
  • Protocol Overview

Concise summary of the Tesamorelin research information.

  • Goal: Research related to Tesamorelin and its association with growth hormone pathways and metabolic processes.
  • Schedule: General research information regarding Tesamorelin.
  • Information: Tesamorelin is a synthetic peptide studied in scientific research.
  • Storage: Refer to product-specific guidelines and manufacturer recommendations for storage information.
  • Dosing Protocol

Research information overview and scientific background.

  • Week 1: Research information related to Tesamorelin studies.
  • Weeks 2+: Research information related to Tesamorelin studies and scientific evaluation.
  • Frequency: General research information regarding Tesamorelin studies.
  • Cycle Length: Information based on published research and scientific studies.
  • Timing: Research context and background information related to Tesamorelin.
  • Storage Instructions

Proper storage preserves peptide quality.

  • Product Storage: Refer to product-specific guidelines and manufacturer recommendations for storage information.
  • Handling Information: Follow appropriate product handling recommendations to maintain product quality.
  • Storage Guidelines: Keep product stored according to the provided product-specific instructions.
  • Important: Refer to official product information for additional storage details.
  • Important Notes

Practical considerations for consistency and safety.

  • Use: Follow product-specific information and recommended guidelines.
  • Handling: Maintain appropriate handling practices to support product quality.
  • Information: Refer to scientific research and product documentation for additional details.
  • Monitoring: Review relevant research information and safety considerations.
  • Documentation: Keep product-related information organized for reference.
  • How This Works

Tesamorelin is a synthetic peptide analog related to growth hormone-releasing hormone (GHRH). It has been studied for its interaction with growth hormone pathways and its role in scientific research related to metabolism and biological processes. Research continues to explore Tesamorelin’s mechanisms, applications, and potential areas of study.

  • Potential Benefits & Side Effects

Observations from clinical research and scientific literature.

  • Significant research interest in Tesamorelin and its relationship with growth hormone pathways.
  • Research exploring metabolic processes and related biological functions.
  • Ongoing studies evaluating Tesamorelin’s potential research applications.
  • Research literature has explored tolerability and observed effects in scientific studies.
  • Lifestyle Factors

Complementary strategies for optimal outcomes.

  • Balanced Nutrition: Maintain a balanced diet to support overall health and wellness.
  • Physical Activity: Regular exercise and healthy activity levels support general metabolic health.
  • Sleep Quality: Prioritize adequate sleep to support overall body functions.
  • Stress Management: Manage stress through healthy lifestyle practices and relaxation techniques.
  • Injection Technique

General product handling and research information.

  • Preparation: Follow appropriate product handling guidelines before use.
  • Handling: Maintain proper hygiene and handling practices according to product recommendations.
  • Administration Information: Refer to product-specific information and professional guidance where applicable.
  • Storage & Care: Follow recommended handling procedures to maintain product quality.
  • Safety: Dispose of materials appropriately and follow relevant safety guidelines.
  • Important Note
This content is provided for educational and research reference purposes only. It does not constitute medical advice, diagnosis, or treatment. Product information should be reviewed carefully, and any health-related decisions should be discussed with a qualified healthcare professional.
  • References

Explore related research dosage protocols and background reading for BPC-157 + TB-500.

Tesamorelin – LiverTox: Clinical and Research Information on Drug-Induced Liver Injury

— National Institutes of Health, NIDDK (2018)
More Info

Tesamorelin (Subcutaneous route) – Drug Information

— Mayo Clinic / IBM Merative (2025)
More Info

Effects of tesamorelin (TH9507), a growth hormone–releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two phase 3 trials

— J. Clin. Endocrinol. Metab. (2010)
More Info

Safety and metabolic effects of tesamorelin in patients with type 2 diabetes: A randomized, placebo-controlled trial

— PLoS ONE (2017)
More Info

Tesamorelin can improve cognitive function (Research Highlight)

— Nature Reviews Endocrinology (2012)
More Info

Tesamorelin Injection – MedlinePlus Drug Information

— MedlinePlus (U.S. National Library of Medicine) (2025)
More Info

EGRIFTA SV (tesamorelin) – Full Prescribing Information

— Theratechnologies, Inc. (FDA Label) (2024)
More Info

Tesamorelin: Uses, Dosage, Side Effects, Warnings

— Drugs.com (AHFS Monograph & Patient Info) (2025)
More Info

Tesamorelin – LiverTox (Safety Profile)

— NIH NIDDK LiverTox Database (2018)
More Info

Administration of Parenteral Medications – Nursing Skills (Open RN Textbook)

— Open RN, Chippewa Valley Technical College (2023)
More Info